共 50 条
- [1] Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (10): : 1279 - 1289Li, YanRamirez-Valle, FranciscoXue, YongjunVentura, Judith I.Gouedard, OlivierMei, JayTakeshita, KenichiPalmisano, MariaZhou, Simon
- [2] Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 346 (02): : 219 - 228Evans, Erica K.Tester, RichlandAslanian, SharonKarp, RussellSheets, MichaelLabenski, Matthew T.Witowski, Steven R.Lounsbury, HeatherChaturvedi, PrasoonMazdiyasni, HormozZhu, ZhendongNacht, MarianaFreed, Martin I.Petter, Russell C.Dubrovskiy, AlexSingh, JuswinderWestlin, William F.
- [3] The novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models[J]. CANCER RESEARCH, 2014, 74 (19)Vidal-Crespo, AnnaRodriguez, VaninaMatas-Cespedes, AlbaCampos, EliasLopez-Guillermo, ArmandoRoue, GaelColomer, DolorsPerez-Galan, Patricia
- [4] Discovery and development of covalent BTK inhibitors[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249Chen, Wei
- [5] Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lyrnphocytic Leukemia (CLL)[J]. BLOOD, 2013, 122 (21)Brown, Jennifer R.Harb, Wael A.Hill, Brian T.Gabrilove, JaniceSharman, Jeff P.Schreeder, Marshall T.Barr, Paul M.Foran, James M.Miller, Thomas P.Burger, Jan A.Kelly, Kevin R.Mahadevan, DarukaMa, ShuoBarnett, EvelynMarine, JeffreyNava-Parada, PilarAzaryan, AdaMei, JayKipps, Thomas J.
- [6] Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies[J]. BLOOD, 2011, 118 (21) : 1487 - 1487Evans, EricaTester, RichlandAslanian, SharonChaturvedi, PrasoonMazdiyasni, HormozPonader, SabineTesar, BethanySheets, MichaelNacht, MarianaStiede, KathrynWitowski, SteveLounsbury, HeatherPetter, RussellBrown, Jennifer R.Burger, Jan A.Singh, JuswinderWestlin, William F.
- [7] The novel BTK inhibitor CC-292 exerts antitumor activity, inhibits proliferation, activation and migration of tumor cells, and overcomes stroma-mediated chemoresistance to bendamustine in CLL[J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 117 - 118Lee, EriongRodriguez, VaninaHanna, BolaYazdanparast, HaniyehRodriguez, MartaAmador, VirginiaMontraveta, ArnauVidal-Crespo, AnnaPerez-Galan, PatriciaCampo, EliasLopez-Guerra, MonicaSeiffert, MartinaColomer, Dolors
- [8] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)[J]. HAEMATOLOGICA, 2014, 99 : 54 - 55Brown, J. R.Harb, W. A.Hill, B. T.Gabrilove, J.Sharman, J. P.Schreeder, M. T.Barr, P. M.Foran, J. M.Miller, T. P.Burger, J. A.Kelly, K. R.Mahadevan, D.Ma, S.Barnett, E.Marine, J.Nava-Parada, P.Azaryan, A.Mei, J.Kipps, T. J.
- [9] A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton's Tyrosine Kinase Inhibitor CC-292[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2021, 379 (02): : 166 - 174Labenski, MattVoortman, LukasMedikonda, Aravind PrasadSherratt, Philip J.Corin, Alan F.
- [10] Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma[J]. ACS CHEMICAL BIOLOGY, 2014, 9 (05) : 1086 - 1091Wu, HongWang, WenchaoLiu, FeiyangWeisberg, Ellen L.Tian, BeiChen, YongfeiLi, BinhuaWang, AoliWang, BeileiZhao, ZhengMcMillin, Douglas W.Hu, ChenLi, HongWang, JinhuaLiang, YankeBuhrlage, Sara J.Liang, JuntingLiu, JingYang, GuangBrown, Jennifer R.Treon, Steven P.Mitsiades, Constantine S.Griffin, James D.Liu, QingsongGray, Nathanael S.